Evaluating markers for treatment selection based on survival time

Statistics in Medicine

Volumn 30, Issue 18, 2011, Pages 2251-2264

  Song, Xiao ^a   Zhou, Xiao Hua ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarker; Restricted survival time; Selection impact curve; Statistical interaction

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; MATHEMATICAL ANALYSIS; MEDICAL DECISION MAKING; NONPARAMETRIC TEST; OUTCOME ASSESSMENT; PARAMETRIC TEST; SURVIVAL RATE; SURVIVAL TIME;

COLONIC NEOPLASMS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PATIENT SELECTION; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR MARKERS, BIOLOGICAL;

EID: 80955180971     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4258     Document Type: Article

References (21)

1. Elmer-Dewitt P, Lemonick M, Park A, Nash M. Medicine: the future of drugs. Time 2001; 57:56-102.
2. Erisman MD, Scott JK, Watt RA, Astrin SM. The c-myc protein is constitutively expressed at elevated levels in colorectal carcinoma cell lines. Oncogene 1988; 2:367-378.
3. Augenlicht L, Wadler S, Corner G, Richards C, Ryan L, Multani A, Pathak S, Benson A, Hailer D, Heerdt B. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Research 1997; 57:1769-1775.
4. Li Y, Ryan L. Inference on survival data with covariate measurement error-an imputation-based approach. Scandinavian Journal of Statistics 2006; 33:169-190.
5. Song X, Pepe MS. Evaluating markers for selecting a patient's treatment. Biometrics 2004; 60:874-883.
6. Zhou XH, Obuchowski NA, McClish DK. Statistical Methods in Diagnostic Medicine. Wiley: New York, 2002.
7. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford University: New York, 2003.
8. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. Springer: New York, 2003.
9. Zhao H, Tsitais AA. A consistent estimator for the distribution of quality adjusted lifetime. Biometrika 1997; 84:339-348.
10. Chen PY, Tsitais AA. Causal inference on the difference of the restricted mean lifetime between two groups. Biometrics 2001; 57:1030-1038.
11. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. Journal of Educational Psychology 1974; 66:688-701.
12. Rubin DB. Bayesian inference for causal effects: the role of randomization. Annals of Statistics 1978; 6:34-58.
13. Holland P. Statistics and causal inference. Journal of the American Statistical Association 1986; 81:945-960.
14. Billingsley P. Probability and Measure. Wiley: New York, 1995.
15. Van der Vaart AW, Wellner JA. Weak Convergence and Empirical Processes. Springer: New York, 2000.
16. Song X, Zhou XH. Evaluating markers for treatment selection based on survival time. Working Paper 349, UW Biostatistics Working Paper Series, 2009. Available from:.
17. Pepe MS. Receiver operating characteristic methodology. Journal of the American Statistical Association 2000; 95:308-311.
18. Pepe MS. Three approaches to regression analysis of receiver operating characteristic curves in medical diagnostic testing. Biometrics 1998; 54:124-135.
19. Heagerty P, Pepe M. Semiparametric estimation of regression quantiles with application to standarizing weight for height and age in U.S. children. Applied Statistics 1999; 48:533-551.
20. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer: New York, 2000.
21. Song X, Ma S, Huang J, Zhou XH. A semiparametric approach for the nonparametric transformation survival model with multiple covariates. Biostatistics 2007; 8:197-211.